Solventum Co. (NYSE:SOLV) Shares Purchased by Captrust Financial Advisors

Captrust Financial Advisors boosted its stake in shares of Solventum Co. (NYSE:SOLV - Free Report) by 43.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 35,165 shares of the company's stock after purchasing an additional 10,611 shares during the period. Captrust Financial Advisors' holdings in Solventum were worth $2,323,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of SOLV. Principal Financial Group Inc. lifted its stake in Solventum by 3.0% during the 3rd quarter. Principal Financial Group Inc. now owns 169,615 shares of the company's stock valued at $11,826,000 after acquiring an additional 4,896 shares during the period. Czech National Bank lifted its stake in Solventum by 6.5% during the 4th quarter. Czech National Bank now owns 29,966 shares of the company's stock valued at $1,980,000 after acquiring an additional 1,820 shares during the period. Oak Thistle LLC acquired a new stake in Solventum during the 4th quarter valued at approximately $512,000. Thurston Springer Miller Herd & Titak Inc. lifted its stake in Solventum by 69.7% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 891 shares of the company's stock valued at $59,000 after acquiring an additional 366 shares during the period. Finally, Wedge Capital Management L L P NC lifted its stake in Solventum by 7.3% during the 4th quarter. Wedge Capital Management L L P NC now owns 75,283 shares of the company's stock valued at $4,973,000 after acquiring an additional 5,094 shares during the period.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. The Goldman Sachs Group boosted their target price on shares of Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a research note on Monday, March 3rd. Morgan Stanley upped their price objective on shares of Solventum from $73.00 to $80.00 and gave the stock an "equal weight" rating in a research report on Wednesday, March 5th. Mizuho upped their price objective on shares of Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a research report on Monday, March 3rd. Wells Fargo & Company upped their target price on shares of Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a report on Friday, February 28th. Finally, Bank of America upped their target price on shares of Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a report on Wednesday, February 26th. One analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $79.00.

Solventum Stock Down 3.5%

Shares of SOLV traded down $2.57 during mid-day trading on Wednesday, hitting $70.95. 1,400,643 shares of the company's stock were exchanged, compared to its average volume of 1,264,082. The company has a market cap of $12.27 billion and a price-to-earnings ratio of 32.85. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $85.92. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The stock's 50-day moving average is $70.07 and its 200-day moving average is $71.29.

Solventum (NYSE:SOLV - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.15. The business had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.02 billion. The firm's revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period in the prior year, the company posted $2.08 EPS. On average, sell-side analysts anticipate that Solventum Co. will post 6.58 earnings per share for the current fiscal year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.